Vincent Colicchio – Vice President, Supply Chain and External Manufacturing for Dr. Reddy’s Laboratories – discusses supply chain, manufacturing and training issues pertaining to generic drug manufacturing.

Dr. Reddy’s Laboratories – one of a handful of Indian drug companies licensed to make a new Covid-19 pill developed by Merck – said on November 15 that the manufacturer was open to making a similar pill from Pfizer, thought to be even more effective.

Dr. Reddy’s Laboratories Ltd. along with the company’s subsidiaries announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, was approved by Health Canada and launched in the Canadian market.

PharmaLive talked to Milan Kalawadia – Senior Vice President, Head of US Commercial Operations for Dr. Reddy’s Laboratories – about facing challenges from the COVID-19 pandemic; obstacles going forward for generic drug companies; customer relationships; and other industry-related topics.